Asthma drug developer raises $17 million

By Martha Sanchez-Avila

SAN FRANCISCO (Private Equity Week) – Last week asthma drug developer Altair Therapeutics raised $17 million in a Series A funding round that was led by Domain Associates and capped a two-year startup financing period.

Other investors in the round include AgeChem Venture Fund, Thomas McNerney & Partners, Forward Ventures and Isis Pharmaceuticals.

Read the rest of this entry »